A dual GLP-1 and GIP receptor agonist used for type 2 diabetes and obesity, enhancing insulin secretion, suppressing glucagon, and promoting weight loss.
Luu. Steven S; Chan. Daryl Emery Chee Yeow DECY; Marshall. Nathaniel S NS; Phillips. Craig L CL; Gru...
A recent review found that tirzepatide, a weightâloss drug, cuts the number of breathing pauses during sleep more than any other medicine studied and also improves how sleepy people feel and their heartâhealth markers. The FDA has now approved it as the first drug you can take for obstructive sleep apnea, making it a real, usable option beyond the usual CPAP machines.
Adam. Shukri S; Ibrahim. Fatma M FM; Dabou. Eman Abdelaziz Ahmed EAA; Pitre. Sneha S; Aiman. Rania R...
People using tirzepatide for weight loss in the real world reported big drops in weight, felt more confident about controlling their eating, and noticed better sleep, energy, mood, and confidence. Side effects were mostly mild stomach issues that went away quickly. The benefits were strongest early on and were higher for those who could afford the drug and had some behavioral support.
A recent study found that tirzepatide, a drug already known for helping people lose weight, also makes sleep apnea much better. It cuts the number of breathing pauses during sleep, improves oxygen levels, lowers blood pressure, and reduces heartâdisease risk, and it does this not just by shedding pounds but also by changing where fat is stored, calming inflammation, and tweaking the nervous system.
The paper says tirzepatide, a dual GLPâ1/GIP drug, can cause big weight lossâsometimes as much as surgeryâwhile also improving blood sugar and heart health. It proposes that obesity comes in four âphenotypesâ (hungry brain, hungry gut, emotional hunger, slow burn) and that matching the right drug to the right phenotype could make treatment even more effective.
Rahman. Muhammad Hafizur MH; Selim. Shahjada S; Afsana. Faria F; Hoque. Md Azizul MA; Saifuddin. M M...
In Bangladeshi adults with type 2 diabetes who fasted for Ramadan, a low weekly dose of tirzepide (2.5âŻmg) safely lowered blood sugar and cut body weight by about 5âŻkg, with only mild stomach upset and no dangerous lowâbloodâsugar episodes.
Tirzepatide can help people with obesity lose weight, but the weight loss often includes loss of muscle and bone. Adding plenty of protein and doing regular resistance (strength) training can protect muscle and bone while youâre on the drug. Be careful using it in kids, teens, or older adults because longâterm safety isnât known, and donât use it only for short, smallâweight drops as you might regain fat quickly.
Horn. Deborah B DB; Linetzky. Bruno B; Davies. Melanie J MJ; Laffin. Luke J LJ; Wang. Hui H; Murphy....
People who lost weight on tirzepatide for 36 weeks got their health markers (waist size, blood pressure, cholesterol, blood sugar, insulin) better, but when the drug was stopped many of them gained back weight and those health gains slipped away. The more weight they regained, the bigger the reversal of the benefits.
Sattar. Naveed N; Scilletta. Sabrina S; Stefanski. Adam A; Wang. Hui H; Daly. Jack W JW; Linetzky. B...
Tirzepatide, a drug already used for weight loss, also drops blood uric acid levels in people with obesity, and most of that drop comes from the weight loss itself. Over 72 weeks, people taking tirzepatide lost up to 21% of their weight and saw uric acid fall by about 0.7â0.95âŻmg/dL, far more than the tiny change on placebo. This suggests the drug could help manage gout risk while youâre losing weight.
Sharafeldin. Mahmoud M; Alhamdan. Noor N; Khaliq. Ayesha A
A 39âyearâold man who was taking tirzepatide for weight loss increased his dose too quickly on his own and ended up in the ICU with dangerous low blood sugar, messedâup electrolytes, low blood counts, pneumonia, and multiple organ failure. He needed a ventilator, kidney dialysis, a tracheostomy, and long rehab before he could recover.
Acosta-Madiedo. Ana Sofia AS; Gutierrez. Marcela M; Gutierrez. Martha M; Villacampa. Alan A; Kerdel....
A small openâlabel trial gave 20 overweight adults with moderateâtoâsevere hidradenitis suppurativa weekly tirzepatide for 24 weeks. Eighty percent hit the main success measure (HiSCR), and participants also reported better skin scores, less pain, and better qualityâofâlife, while losing weight. The drug was well tolerated and benefits lingered a bit after stopping.
Tirzepatide, a drug that activates two gut hormones, helps people lose weight and improves metabolism. Early studies show it can also lower the number of breathing pauses (AHI) in sleep apnea, likely by shrinking fat around the airway and cutting inflammation. This means it might be a useful tool for biohackers looking to boost sleep quality and overall health, but it still needs a doctorâs prescription and monitoring.
A 66âyearâold man with severe obesity and several health problems got a fastâtrack increase of tirzepatide from 2.5âŻmg to 12.5âŻmg in four months. He lost a lot of weight but then developed acute kidney injury (AKI) with high potassium and acidosis. The kidney problem got better after stopping the drug, giving fluids, and treating the high potassium. The case suggests that rapid dose jumps, dehydration from GI side effects, and many other medicines can hurt the kidneys.
Ritzel. Robert R; Davies. Melanie J MJ; Hao. Lichen L; Ji. Linong L; Mk. Lintu L; Mabunay. Aileen A;...
For people with type 2 diabetes who are already on tirzepatide but still have an A1c above 7%, adding or switching to the longâacting insulin glargine 300 (Glaâ300) can drop A1c by about 1.3% over six months, with roughly oneâquarter of users hitting the <7% target and no reported lowâbloodâsugar events.
Funamizu. Noriko N; Funamizu. Naotake N; Hirose. Tsunemichi T
A 48âyearâold man with typeâ2 diabetes, severe obesity and sleep apnea lost a lot of weight after starting tirzepatide, which also lowered his blood sugar. As he got thinner, his sleepâapnea numbers on the CPAP machine dropped, and he was eventually able to stop using CPAP under medical supervision. No serious side effects were reported.
Siddiqi. Ahmed Kamal AK; Khan. Muhammad Shahzeb MS; Kulkarni. Anandita A; Hall. Michael E ME; Bö...
The review shows that drugs normally used for diabetes, especially tirzepatide, can also drop blood pressure. SGLT2 inhibitors lower systolic pressure by about 2â4âŻmmHg, while most GLPâ1 agonists only shave off 1â5âŻmmHg. Tirzepatide stands out, cutting systolic pressure by roughly 10âŻmmHg in some highârisk groups, making it a promising addâon for people looking to improve heart health alongside metabolic goals.
Angelopoulos. Nikolaos N; Androulakis. Ioannis I; Rizoulis. Andreas A; Boniakos. Anastasios A; Foust...
A 12âweek realâworld trial gave people with obesity but no diabetes a low dose of tirzepatide (starting at 2.5âŻmg, then 5âŻmg weekly). On average they lost about 7âŻ% of their body weight (â8âŻkg) and almost half lost at least 5âŻ% of their weight, with small improvements in blood sugar and cholesterol and few side effects.
In a Japanese obesity study, weekly tirzepatide injections (10âŻmg or 15âŻmg) led to big weight drops over 72 weeks, with women and people with a lower starting BMI losing a bit more. Almost everyone on tirzepatide lost at least 5% of their weight, while only a few on placebo did. Blood sugar, cholesterol, and other heartârelated numbers also improved, and sideâeffects were similar across groups.
Zhang. Ju J; Guan. Xiangfeng X; Kong. Mowei M; Xia. Meng M; Yu. Yang Y; Zhang. Chunxiang C
This review shows that tirzepatide (and similar GLPâ1 drugs) not only helps control blood sugar but also cuts the risk of dying from any cause or from heart problems in people with heart or kidney disease, especially if theyâre overweight. It may also lower the chance of ending up in the hospital for heartâfailure among obese patients.
Snaith. Jennifer R JR; Frampton. Ruth R; Samocha-Bonet. Dorit D; Greenfield. Jerry R JR
In a small 12âweek study, people with typeâŻ1 diabetes who were also obese lost about 10âŻkg (almost 9% of body weight) when they took weekly injections of tirzepatide, while those on placebo barely lost any weight. The drug also lowered bloodâsugar (HbA1c) a little and let participants cut their daily insulin dose by about a third, with no major safety problems reported.
Khurshid. Bakht Noor BN; Moazzam. Ukasha U; Dimitropoulos. Ioannis I
A 19âyearâold man with autism, ADHD, type 2 diabetes and severe earlyâonset obesity saw big improvements after starting tirzepatide, a drug that activates two gut hormones. Even though he didnât have a known genetic cause for his overeating, his weight, appetite and blood sugar got much better, showing tirzepatide could work for teens with hardâtoâtreat obesity and hyperphagia.